🟢 Connect Biopharma is trading 10.61% up in pre-market; no clear catalyst identified

Connect Biopharma is trading 10.61% up at $2.04, with no clear company-specific catalyst identified for September 8, 2026.

• Phase 2 Seabreeze STAT asthma and COPD topline results remain expected during September, creating potential event anticipation.
• No new results or announcement were found.
• Broader sentiment is cautious, making the move appear speculative rather than driven by market strength or confirmed company news.